P2RX7 and graft versus host disease: Collectively, this data suggests Hu-PBMC-NSG mice provide a pre-clinical model of GVHD in which new therapeutics aimed at inhibiting P2X7 receptor activation can be tested, whilst the potential use of this model to test new therapeutics aimed at activating A2A receptors remains to be established.